Quick answer: For ophthalmology and dermatology practices on Nextech, Nextech prior authorization automation is most valuable when applied to high-cost biologics (Dupixent, Skyrizi, Cosentyx), surgical and injectable treatments (cataract surgery, Eylea, Lucentis), and visit-frequency-limited services where manual PA workflow would otherwise create a 1–2 week revenue lag. Nextech's specialty-tuned templates feed the ePA module directly, so the auth team starts the PA workflow on the same day the order is placed rather than discovering the requirement when the patient calls to schedule. The bottlenecks that remain — peer-to-peer reviews, payer-specific clinical criteria for biologics, and mid-year formulary changes — are where a dedicated AI PA agent layered on top of Nextech closes the gap.
Why ophthalmology and dermatology have high PA volume
Ophthalmology and dermatology sit in a small group of specialties where prior authorization volume isn't a side workflow — it's a primary operational bottleneck. The reason is structural to the specialty itself.
Ophthalmology practices order high-cost injectable treatments (anti-VEGF injections like Eylea and Lucentis for wet AMD and DME), high-volume surgical procedures (cataract surgery, retinal procedures, glaucoma surgeries), and imaging studies that payers tightly police for medical necessity. Each of these requires PA at most major commercial payers and an increasing share of Medicare Advantage plans. A typical multi-provider ophthalmology practice runs 30–80 PA submissions per provider per week depending on procedure mix and payer concentration.
Dermatology practices order high-cost biologics for chronic inflammatory conditions (Dupixent for atopic dermatitis, Skyrizi and Tremfya for psoriasis, Cosentyx for psoriatic arthritis), Mohs procedures, and an expanding list of injectables and infusions that payers require PA for. Each biologic has its own PA criteria at each payer — step-therapy requirements, prior treatment documentation, severity thresholds — and the payer policies change frequently enough that maintaining the rule set manually is itself a meaningful workload. A typical multi-provider dermatology practice with a biologics-heavy patient panel runs 40–70 PA submissions per provider per week.
Both specialties sit downstream of the AMA's reported 13–16 hours per week of staff PA effort, with the upper end of that range concentrated at specialty practices where PA volume is at the dermatology and ophthalmology baselines.
How Nextech's specialty templates feed the PA workflow
Nextech is a specialty-focused EHR with dedicated templates and workflows for ophthalmology, dermatology, plastic surgery, orthopedics, and urology — recognized as Best in KLAS Ambulatory Specialty EHR for multiple consecutive years. The specialty-tuned templates are what makes the PA automation work at specialty scale: the chart already captures the structured data the PA submission needs, in the format the PA workflow expects.
For ophthalmology, the templates capture the structured fields the PA submission requires: laterality, visual acuity, OCT findings, IOP measurements, prior anti-VEGF treatment history, intraocular lens calculations. When a provider orders an Eylea injection or cataract surgery, the PA automation pulls the relevant fields directly from the encounter note and the prior visit history.
For dermatology, the templates capture the diagnosis-specific clinical evidence biologics require: PASI/BSA scores for psoriasis, EASI/IGA scores for atopic dermatitis, biopsy results for Mohs, prior systemic and topical treatment history with documented failure or intolerance. When a provider orders Dupixent for a patient with atopic dermatitis or Skyrizi for psoriasis, the PA automation pulls the right severity scoring and prior treatment documentation into the submission.
This is the part that differentiates Nextech prior authorization automation at specialty practices from generic EHR PA automation. The submission isn't pulling generic fields from a generic chart; it's pulling specialty-specific clinical evidence from a specialty-tuned chart. The auth team's review starts from a much more complete first draft.
The dermatology-specific patterns Nextech PA automation handles
Dermatology PA volume concentrates in three categories, and Nextech's automation handles each one differently.
Biologics for chronic inflammatory conditions. PA submissions for biologics like Dupixent, Skyrizi, Tremfya, Cosentyx, and Taltz require specific clinical evidence at each payer: diagnosis confirmation (often biopsy-supported), severity scoring (PASI, EASI, BSA, IGA, depending on indication and payer), prior treatment history with documented step-therapy completion, and contraindications check. Nextech's dermatology templates capture these fields during the encounter, and the PA automation pulls them into the submission. For the major commercial payers that support ePA, the submission goes out same-day; for payers that don't, the packet is built but a staff member sends through the payer's portal.
Mohs procedures and surgical pathology. PA for Mohs surgery requires diagnosis, location, prior treatment history, and often photo documentation. The automation pulls the path report and the relevant encounter data. The submission usually goes through ePA cleanly at major commercial payers.
Phototherapy and high-cost injectable treatments. PA for in-office injectables (Kenalog injections, intralesional injections for keloids and alopecia) and phototherapy series requires documentation of prior treatment failure and clinical justification. Nextech's automation handles the routine cases; specialty payer policies for unusual indications still require auth team judgment.
The cumulative effect at a typical 6–10 provider dermatology practice is that Nextech's PA automation handles roughly 60–70% of the submission workload cleanly, with the rest concentrated in the long tail of payer-specific clinical criteria and mid-year formulary changes that the rule library hasn't caught up to.
The ophthalmology-specific patterns Nextech PA automation handles
Ophthalmology PA volume concentrates in four categories, each with its own clinical evidence requirement.
Anti-VEGF injections (Eylea, Lucentis, Avastin, Vabysmo). These are the highest-volume PA workflow at most retinal practices and medical retina-heavy ophthalmology groups. PA requires diagnosis (wet AMD, DME, RVO), OCT findings, visual acuity, and prior injection history. Nextech's ophthalmology templates capture all of these fields during the encounter; the automation pulls them into the submission. Most major commercial payers and Medicare Advantage plans handle the submission through ePA.
Cataract surgery and refractive procedures. PA for cataract surgery requires diagnosis, visual acuity documentation, glare/contrast sensitivity testing, IOL selection, and laterality. Some payers require pre-operative visit documentation establishing medical necessity. Nextech's automation pulls the relevant fields, with payer-specific clinical criteria handled in the rule library.
Retinal surgery and posterior segment procedures. PA for vitrectomy, retinal detachment repair, and posterior segment procedures requires more extensive clinical documentation — imaging findings, prior treatment history, surgical planning. These submissions tend to require more auth team judgment because the clinical criteria vary more across payers.
Imaging studies and advanced diagnostics. OCT, fluorescein angiography, and visual field testing PA requirements vary by payer and frequency limit. The automation handles the routine cases; visit-frequency-limited services need rules that account for the patient's recent imaging history.
At a multi-provider ophthalmology practice with mixed medical retina, surgical, and general ophthalmology volume, Nextech's PA automation typically handles 55–70% of submissions cleanly, with the rest in the long tail.
Where the long tail breaks Nextech's native rules
For both specialties, the same four categories of work fall outside Nextech's native PA automation and require either auth team judgment or a dedicated AI agent on top.
Peer-to-peer reviews. When a payer denies an initial PA submission and offers a peer-to-peer, the provider has to schedule and conduct a phone call with the payer's medical director. Specialty practices with biologic-heavy or surgical-heavy panels often run 3–6 peer-to-peers per provider per week. The automation routes the request and tracks the outcome; the call itself stays manual.
Payer-specific clinical criteria not modeled in Nextech's rule library. Some payers maintain narrow medical-policy criteria for specialty biologics and procedures — specific prior treatments tried and failed, particular diagnostic thresholds, named clinical trial enrollment exclusions. The rule library captures the major patterns but doesn't always reflect the niche payer policies, particularly for smaller commercial plans and state Medicaid managed care.
Mid-year formulary and policy changes. Payers update biologic formulary tiers and PA requirements quarterly or more often. Nextech's rule library updates on its own cadence. The window between a payer changing a policy and the library catching up is where unexpected denials happen.
Non-ePA payer submissions. Major commercial payers and Medicare Advantage support ePA. The long tail of smaller commercial plans, some state Medicaid managed care plans, and worker's comp carriers still require fax or portal submission. The automation can compile the packet but a staff member has to send manually.
These four categories typically account for 30–45% of the PA workload at specialty practices on Nextech, depending on payer mix and specialty volume concentration.
Layering an AI agent on top for the specialty long tail
For ophthalmology and dermatology practices where the long tail is the operational bottleneck, a dedicated AI prior authorization agent on top of Nextech is the layer that closes the gap.
The AI agent adds capabilities Nextech's native automation doesn't cover at specialty scale: deeper payer-rule modeling across hundreds of plans (including the niche payers Nextech's library doesn't reach), specialty-aware clinical-data extraction that captures the right severity scoring and prior treatment evidence for each biologic at each payer, denial prediction that flags submissions likely to be denied before they go out, and non-ePA channel coverage for the payer mix Nextech can't fully reach.
Honey Health's Prior Authorization agent is the canonical implementation of this layered pattern for specialty practices on Nextech. The agent reads orders from Nextech, applies its own ophthalmology- and dermatology-aware payer-rule and clinical-criteria modeling on top of Nextech's flagging, handles submission across ePA, portal, fax, and phone channels, and writes PA status back into the Nextech work queue so the auth team operates in one place. The same architecture extends across eligibility verification, denial management, refill management, fax triage, and payment posting — so specialty practices adopting AI PA automation as the first step can extend automation across the rest of the back office without changing vendors and without disrupting the specialty-specific charting flow Nextech already provides.
The math at a typical 6-provider dermatology or ophthalmology practice usually pencils out when PA volume is 40+ per provider per week and the practice is absorbing meaningful labor or revenue loss in the long tail. Below that volume, Nextech's native automation alone is often enough.
Frequently asked questions
Does Nextech's PA automation handle the specific clinical criteria for biologics like Dupixent or Skyrizi?
The automation handles the routine PA criteria for major commercial payers and Medicare Advantage plans well — diagnosis, severity scoring (PASI, EASI, BSA), and standard prior treatment documentation. Where it falls short is on the niche payer policies that aren't fully encoded in the rule library: state Medicaid managed care variations, smaller commercial plans, and policies that changed mid-year. The auth team usually has to handle those manually or layer in an AI agent that models the long tail.
How does the automation work for visit-frequency-limited services like phototherapy or anti-VEGF injections?
Nextech's automation tracks the patient's recent service history and applies the payer's frequency rules to the new order. For phototherapy series or anti-VEGF injection schedules, the system flags PA requirements based on the patient's current treatment cycle and the payer's frequency limits. This catches the most common visit-limit issues before the order is sent to scheduling.
What happens when a payer changes a biologic's PA requirements mid-year?
Nextech's rule library updates on its own cadence after a payer policy change, which usually trails the payer's effective date by several weeks. During that window, the automation may submit PAs against an outdated rule set and the denial routes back into the auth team's queue. The fix is a monthly review where the auth team checks denied PAs against current payer policy and flags any rule gaps to update.
Do peer-to-peer reviews go through the automation, or does the provider have to handle them manually?
The automation routes the peer-to-peer request and tracks the outcome, but the call itself is provider-to-physician and stays manual. For practices with high peer-to-peer volume, the automation can surface the clinical evidence the provider needs for the call (prior treatment history, severity scoring, imaging findings) so the provider doesn't have to gather it manually before each call. A dedicated AI agent on top of Nextech typically does this better than the native automation.
Can the automation handle PAs for in-office injectables that aren't biologics?
Yes. PAs for in-office injectables like intralesional triamcinolone, keloid injections, and alopecia treatments work through the same workflow as biologics — the automation captures the diagnosis, prior treatment documentation, and clinical justification from the chart and assembles the submission. The volume is usually lower than biologics, but the workflow is the same.
